Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trialMichael Weller, Maciej M. Mrugała, Nicholas Butowski et al.|The Lancet Oncology|2017Cited by 1.1k
Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II StudyAndrew B. Lassman, Patrick Roth, Juan Manuel Sepúlveda-Sánchez et al.|Zurich Open Repository and Archive (University of Zurich)|2022Cited by 76
Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNUCandelaria Gomez‐Manzano, Morris D. Groves, Ju He et al.|International Journal of Oncology|2001Cited by 25
OS10.6 Infigratinib (BGJ398) in patients with recurrent gliomas with fibroblast growth factor receptor (FGFR) alterations: a multicenter phase II studyAndrew B. Lassman, Patrick Roth, Juan Manuel Sepúlveda-Sánchez et al.|Neuro-Oncology|2019Cited by 11
ACTR-33. INFIGRATINIB (BGJ398) IN PATIENTS WITH RECURRENT GLIOMAS WITH FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR) ALTERATIONS: A MULTICENTER PHASE II STUDYAndrew B. Lassman, Patrick Roth, Juan Manuel Sepúlveda-Sánchez et al.|Neuro-Oncology|2019Cited by 8